Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ionis Pharmaceuticals

28.40
+0.05000.18%
Post-market: 28.400.00000.00%16:25 EDT
Volume:841.01K
Turnover:23.81M
Market Cap:4.51B
PE:-9.35
High:28.76
Open:28.31
Low:28.04
Close:28.35
Loading ...

Ionis ‘remains confident in pelacarsen’ after Novartis update on Phase 3 timing

TIPRANKS
·
31 Jan

FDA & EMA Accept Biogen's Filings for Higher Dose SMA Drug

Zacks
·
24 Jan

Biogen Gets U.S., European Reviews of Higher-Dose Spinraza

Dow Jones
·
23 Jan

Biogen Gets FDA, EMA Approval to Study Higher Dose Regimen of Spinal Muscular Atrophy Treatment

MT Newswires Live
·
23 Jan

FDA and Ema Accept Applications for Higher Dose Regimen of Nusinersen in Sma

THOMSON REUTERS
·
23 Jan

Ionis Pharmaceuticals Insiders Sold US$3.2m Of Shares Suggesting Hesitancy

Simply Wall St.
·
23 Jan

S&P 500 Futures Climb In Premarket Trading; Tempus AI, IDACORP Lead

Dow Jones
·
21 Jan

Intellia Loses 21.6% in a Week: How Should You Play the Stock?

Zacks
·
18 Jan

Why Ionis Pharmaceuticals (IONS) Is the Biotech Stock with Biggest Upside Potential

Insider Monkey
·
18 Jan

Ionis Pharmaceuticals: Strong Pipeline and Market Potential Drive ‘Buy’ Rating

TIPRANKS
·
17 Jan

Ionis Pharmaceuticals (IONS) Gets a Hold from Bernstein

TIPRANKS
·
16 Jan

Ionis Pharmaceuticals Price Target Maintained With a $70.00/Share by RBC Capital

Dow Jones
·
15 Jan

Ionis Pharmaceuticals: Strategic Path to Cash Flow Positivity and Strong Pipeline Drive Buy Rating

TIPRANKS
·
14 Jan

Ionis Pharmaceuticals: Hold Rating Amid Uncertainty in Future Financial Performance

TIPRANKS
·
14 Jan

Ionis unveils pipeline plan for 2025, expects 4 independent product launches

TIPRANKS
·
14 Jan

Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock?

Zacks
·
09 Jan

Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected

Benzinga
·
08 Jan

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and Anteris Technologies Global Corp. (AVR)

TIPRANKS
·
07 Jan

Ionis Pharmaceuticals Inc : Bofa Global Research Cuts Price Objective to $65 From $66

THOMSON REUTERS
·
06 Jan

AstraZeneca Stock Down Almost 14% in 3 Months: Time to Sell?

Zacks
·
06 Jan